ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes

Autor: Jessica W. Chen, William Jacot, Javier Cortés, Ian E. Krop, Susan Dent, Nadia Harbeck, Michelino De Laurentiis, Véronique Diéras, Young‐Hyuck Im, Thomas J. Stout, Frauke Schimmoller, Heidi M. Savage, Katherine E. Hutchinson, Timothy R. Wilson

Publikováno v: Molecular Oncology, Vol 17, Iss 10, Pp 2000-2016 (2023)

Taselisib is a potent β‐sparing phosphatidylinositol 3‐kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha (PIK3CA)‐mutated (PIK3CAmut) advance

Externí odkaz: https://doaj.org/article/535a6a7921404a8298c1f95b55637007

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel–Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study

Autor: Marc Bardou, Pierre Vabres, Laurence Faivre, Annabel Maruani, Victoria E R Parker, A. Phan, Christine Chiaverini, L. Martin, Jill Clayton-Smith, C. Fleck, Maxime Luu, Tristan Mirault, Fanny Morice-Picard, M. Carpentier, Marie-Line Jacquemont, Hervé Devilliers, Marjolaine Willems, A. Maurer, Romaric Loffroy, Didier Bessis, Florence Petit, Robert K. Semple, M. Yousfi

Publikováno v: Genetics in Medicine
Genetics in Medicine, Nature Publishing Group, 2021, ⟨10.1038/s41436-021-01290-y⟩
Luu, M, Vabres, P, Devilliers, H, Loffroy, R, Phan, A, Martin, L, Morice-Picard, F, Petit, F, Willems, M, Bessis, D, Jacquemont, M-L, Maruani, A, Chiaverini, C, Mirault, T, Clayton-Smith, J, Carpentier, M, Fleck, C, Maurer, A, Yousfi, M, Parker, V E R, Semple, R K, Bardou, M & Faivre, L 2021, ' Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and KLIPPEL TRENAUNAY SYNDROME (KTS): the TOTEM trial, a phase 1/2 multicentre, open-label, single-arm study ', Genetics in Medicine . https://doi.org/10.1038/s41436-021-01290-y

International audience; ABSTRACT Purpose PIK3CA pathogenic variants in the PIK3CA-related overgrowth spectrum (PROS) activate phosphoinositide 3-kinase signaling, providing a rationale for targeted therapy, but no drug has proven efficacy and safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb35a651c9d3e22a4c1a05d557c9a14
https://doi.org/10.1038/s41436-021-01290-y

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

Autor: J.Y. Hsu, Na Cui, Susan Dent, Sofia Sousa, Timothy R. Wilson, Véronique Diéras, William Jacot, Ian E. Krop, Frauke Schimmoller, M. De Laurentiis, Nadia Harbeck, Yunjoo Im, Jing He, J. Cortes, Pamela Drullinsky

Publikováno v: Annals of Oncology. 32:197-207

Background The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic breast cancer. Patients and method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bdee42c75cb939356b9f98869998bca
https://doi.org/10.1016/j.annonc.2020.10.596